Yongqiang Lin

Dr. Yongqiang Lin


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 September 2024 in Pharmacological Research
Verified
Journal Article
Open access
TZTian-Tian Zuo
Tian-Tian Zuo
JLJing Liu
Jing Liu
KZKe Zan
Ke Zan
LLLi-Na Liu
Li-Na Liu
QWQi Wang
Qi Wang
YLYongqiang Lin
Yongqiang Lin
Scientific risk assessment of exogenous and endogenous toxic substances in traditional Chinese medicine (TCM) is of great significance. The present review comprises a comprehensive summary of progress in the health risk assessment of harmful exogenous substances in TCMs. Such substances include heavy metals, pesticide residues, biotoxins, and endogenous toxic components involving pyrrolizidine alkaloids. The review also discusses the strengths and weaknesses of various bioaccessibility and bioavailability models, and their applications in risk assessment. Future avenues of risk assessment research are highlighted, including further exploration of risk assessment parameters, innovation of bioaccessibility and bioavailability techniques, enhancement of probabilistic risk assessment combined with bioavailability, improvement of cumulative risk assessment strategies, and formulation of strategies for reducing relative bioavailability (RBA) values in TCMs. Such efforts represent an attempt to develop a risk assessment system that is capable of evaluating the exogenous and endogenous toxic substances in TCMs to ensure its safe use in clinics, and to promote the sustainable development of the TCM industry.

23 March 2023 in Frontiers in Pharmacology
Verified
Journal Article
Open access
KZKe Zan
Ke Zan
ZWZhao Wang
Zhao Wang
XHXiao-Wen Hu
Xiao-Wen Hu
YLYao-Lei Li
Yao-Lei Li
YWYing Wang
Ying Wang
YLYongqiang Lin
Yongqiang Lin
Objective: The aim of this study was to systematically explore the pyrrolizidine alkaloids (PAs) type, content and risk assessment in the three Boraginaceae used in TCM, involving Arnebia euchroma (AE), A. guttata (AG), and Lithospermum erythrorhizon (LE).Method: A UHPLC–MS/MS method was established to simultaneously determine eight pyrrolizidine alkaloids (PAs), namely intermedine, lycopsamine, intermedine N-oxide, lycopsamine N-oxide, 7-acetyllycopsamine, 7-acetyllycopsamine N-oxide, echimidine N-oxide, and echimidine in the three herbs. Based on these results, the risk assessment was explored using the routine margin of exposure (MOE) combined with relative potency (REP) for oral and external usage, respectively.Results and Conclusion: Imermedine and imermedine N-oxide were common components in the eight tested PAs. 7-acetyllycopsamine and its N-oxide were not detected in AE; echimidine and its N-oxide were not detected in AG; lycopsamine and its N-oxide, 7-acetyllycopsamine and its N-oxide were not detected in LE. The total contents of 8 PAs in 11 batches of AG was341.56–519.51 μg/g; the content in 15 batches of LE was 71.16–515.73 μg/g, and the content in 11 batches of AE was 23.35–207.13 μg/g. Based on these results, the risk assessment was explored using MOE combined with REP for oral and external usage, respectively. The findings of the risk assessment method of PAs based on MOE combined with the REP factor were consistent with the clinical toxicity results. As an oral herb, AE had low risk or no risk due to its low PA contents, and individual batches of LE were medium risk, while attention should be paid to their clinical use.AG was also low risk. The external use of the three Boraginaceae used in TCM was not associated with any risk. This study systematically explored the PA type and content of the three Boraginaceae used in TCM. Additionally, the refined risk assessment of PAs based on REP provided a more scientific basis for quality evaluation and rational use of the medicinal Boraginaceae used in TCM to improve public health.

9 July 2021 in Journal of Separation Science
Verified
Journal Article
Closed access
PDF file
KZKe Zan
Ke Zan
XHXiaowen Hu
Xiaowen Hu
YLYaolei Li
Yaolei Li
YWYing Wang
Ying Wang
HJHongyu Jin
Hongyu Jin
YLYongqiang Lin
Yongqiang Lin

17 September 2020 in Research Square
Verified
Preprint
Open access
PDF file
QWQingjun Wang
Qingjun Wang
XYXinlan Yu
Xinlan Yu
LSLei Sun
Lei Sun
RTRuntao Tian
Runtao Tian
HHHuaizhen He
Huaizhen He
YLYongqiang Lin
Yongqiang Lin
Background: Fingerprint analysis and simultaneous multi-components determination are crucial for the holistic quality control of traditional Chinese medicines (TCMs). Yet, reference standards (RS) are often commercially unavailable and with other shortages, which severely impede the application of these technologies. Methods: A digital reference standard (DRS) strategy and the corresponding software called DRS analyzer, which supports chromatographic algorithms, spectrum algorithms, and the combination of these algorithms, was developed. The extensive function also enabled the DRS analyzer to recommend the chromatographic column based on big data.Results: Various quality control methods of fingerprints of 11 compounds in polyphenolic acid extract of Salvia miltiorrhiza (S. miltiorrhiza) were developed based on DRS analyzer, involving relative retention time (RRT) method, linear calibration using two reference substances (LCTRS) technique, RRT combined with Photon Diode Array (PDA) method, LCTRS combined with PDA method. Additionally, the column database of samples was established. Finally, our data demonstrated that the DRS analyzer could accurately identify 11 compounds of the samples, using only one or two physical RSs. Conclusions: The DRS strategy is an automated, intelligent, objective, accurate, eco-friendly, universal, sharing, and promising method for overall quality control of TCMs that requires the usage of fewer RSs.

30 March 2021 in Research Square
Verified
Preprint
Open access
PDF file
TZTiantian Zuo
Tiantian Zuo
FLFei-Ya Luo
Fei-Ya Luo
HHHuai-Zhen He
Huai-Zhen He
HJHong-Yu Jin
Hong-Yu Jin
LSLei Sun
Lei Sun
LHLang-Chong He
Lang-Chong He
Little data are available about the extent of bio-accumulation of heavy metals in traditional animal medicines (TAMs). In the present study, the oral bioavailability of cadmium (Cd) in earthworms and leeches was investigated through in vitro PBET digestion/Caco2 and MDKC cell models. We are the first to create an innovative assessment strategy which has capacity to offer a more precise evaluation of Cd-associated health risks in TAMs, by combinational usage of bioavailable Cd levels, the duration and frequency of the exposure to TAMs obtained by questionnaire data, as well as safety factor of TAMs. Our data showed that the percentage of bioavailability for Caco-2 cells in earthworms and leeches ranged from 3.29–14.17% and 4.32–12.61%, respectively. The percentage of bioavailability of MDCK cells in earthworms and leeches ranged from 4.83–15.74% and 6.53–15.04%, respectively. After adjusting by the bioavailability of Cd to target hazard quotient (THQ), excitingly, our findings manifested that the health risks induced by the ingestion of earthworms and leeches were acceptable in the clinic. Our novel strategy has capacity to offer a more realistic and accurate assessment of Cd-associated health risks in TAMs. Besides, our key findings suggest that bioavailability characterization cannot be ruled out and health risks should be assessed on the basis of the bioavailable Cd levels rather than total levels.